Medtronic Gobbles Up ATS Medical As Heart Valve Device Consolidation Continues

The consolidation trend within the heart valve industry continued yesterday as ATS Medical was purchased by Medtronic in a cash deal valued at $350 million. So you know, that is a 54% premium to ATS’ market capitalization on Wednesday. As a result, ATS’s stock soared $2.59 to $4.00.

ATS Medical Acquired By Medtronic For $350 million

In a statement, Medtronic said that the ATS acquisition would further help its ongoing expansion of cardiac surgery devices, including heart valve treatment. This marks the third significant acquisition for Medtronic in the heart valve space during the past fourteen months. As you might recall, Medtronic purchased minimally invasive specialists CoreValve and Ventor Technologies last February for over $1 billion.

Although ATS Medical is widely known for its quiet Open Pivot mechanical heart valve replacement, it too has a stake in the minimally invasive arena with its stentless 3f Aortic Valve Bioprosthesis. We have seen this valve prominently featured following its use in robotic aortic valve replacement surgery by surgeons including Dr. Husam Balkhy. ATS also maintains a unique CryoMaze family of ablation products.

3f Aortic Valve Bioprothesis By ATS Medical

As with most transactions, this deal is dependent on the approval of ATS shareholders and regulatory agencies. Interestingly enough, both companies are based in Minneapolis. Following this announcement, it will be very interesting to see how the heart valve device industry further consolidates.

Keep on tickin!

Adam Pick
Written by Adam Pick

Adam Pick is a patient, author of The Patient's Guide To Heart Valve Surgery and the founder of

To learn how Adam has helped millions of people with heart valve disease, watch Adam's video, subscribe to his free newsletter, or visit his Facebook, or Twitter pages.

Have A Question? Call Us at (888) 725-4311
P.O. Box 4049
Redondo Beach, CA 90277
Phone: (888) 725-4311